Jagiellońskie Centrum Innowacji Sp. z o.o.
- Address
- lock Available on a paid plan
Jagiellońskie Centrum Innowacji - Advanced Clinical Research Center
Jagiellońskie Centrum Innowacji is a comprehensive clinical research facility conducting cutting-edge trials across multiple therapeutic areas. The center demonstrates particular expertise in oncology research, with extensive experience in advanced and metastatic cancers, including breast cancer, prostate cancer, ovarian cancer, lung cancer, and cervical cancer. Their portfolio encompasses novel targeted therapies, immunotherapies, and combination treatment approaches for solid tumors.
- Oncology trials focusing on metastatic castration-resistant prostate cancer, hormone receptor-positive breast cancer, and platinum-sensitive ovarian cancer
- Vaccine immunology studies including meningococcal and pneumococcal conjugate vaccines in pediatric populations
- Dermatology research investigating treatments for acne vulgaris, plaque psoriasis, chronic spontaneous urticaria, and prurigo nodularis
- Musculoskeletal and metabolic studies including knee osteoarthritis and cancer cachexia
The center's capabilities extend to complex Phase 2 and Phase 3 clinical trials, demonstrating proficiency in both early-stage dose-finding studies and large-scale randomized controlled trials. Their research infrastructure supports diverse study designs including double-blind, placebo-controlled trials, active comparator studies, and innovative combination therapy investigations across pediatric and adult populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 15 of 120 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 116 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Pfizer Inc.5active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.11trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Jagiellońskie Centrum Innowacji Sp. z o.o.
lock Showing 1 of 38 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 120 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fulvestrant | 3 | Unknown | 2023-06-05 | 2025-11-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.